These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Vincristine treatment for management of alarming hemangiomas in infancy].
    Author: Hoyoux C.
    Journal: Rev Med Liege; 2008 Jan; 63(1):14-7. PubMed ID: 18303680.
    Abstract:
    Hemangioma is the most benign vascular tumor encountered in infancy; its incidence is 10-12% at 1 year of age. It usually appears a few weeks after birth, and rather rapidly grows until the age of 10-12 months; it then stabilizes and spontaneously regresses towards a complete disappearance over 5 - 10 years. Therefore, most hemangiomas need no treatment, but just a close clinical follow up. However, some hemangiomas (10-20% of cases), because of their location and/or complications, can have very serious aesthetic, functional, or even vital consequences: these require a more aggressive approach. A pharmacologic initial therapy based on high doses of corticosteroids or interferon alpha 2a or 2b has gained wide acceptance, but can entail serious side-effects. Vincristine represents a safe and effective treatment option for the management of those alarming hemangiomas.
    [Abstract] [Full Text] [Related] [New Search]